Publications by authors named "Keith C Deen"

Claim this Profile
Q
Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.
Jennifer L Beaumont, John M Salsman, Jose Diaz, Keith C Deen, Lauren McCann

Cancer· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
Cora N Sternberg, Ian D Davis, Keith C Deen, Entisar Sigal, Robert E Hawkins

Oncology· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health care costs among renal cancer patients using pazopanib and sunitinib.
Ryan N Hansen, Michelle D Hackshaw, Saurabh P Nagar, Bhakti Arondekar, Keith C Deen

J Manag Care Spec Pharm· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis